MX392115B - Composiciones que comprenden colina. - Google Patents

Composiciones que comprenden colina.

Info

Publication number
MX392115B
MX392115B MX2018011270A MX2018011270A MX392115B MX 392115 B MX392115 B MX 392115B MX 2018011270 A MX2018011270 A MX 2018011270A MX 2018011270 A MX2018011270 A MX 2018011270A MX 392115 B MX392115 B MX 392115B
Authority
MX
Mexico
Prior art keywords
compositions including
single dose
dose form
choline
including choline
Prior art date
Application number
MX2018011270A
Other languages
English (en)
Other versions
MX2018011270A (es
Inventor
Jonathan Bortz
Original Assignee
Balchem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balchem Corp filed Critical Balchem Corp
Publication of MX2018011270A publication Critical patent/MX2018011270A/es
Publication of MX392115B publication Critical patent/MX392115B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona una composición en forma de dosis individual para optimizar la relación entre las vías de "folato-cobalamina" y "colina-betaína". Las composiciones en forma de dosis individuales descritas en la presente aseguran una ingesta de los compuestos que limitan la velocidad que han demostrado que reducen la eficiencia de este eje metabólico vital, y los métodos para usarlo.
MX2018011270A 2016-03-22 2017-03-20 Composiciones que comprenden colina. MX392115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662311590P 2016-03-22 2016-03-22
PCT/US2017/023195 WO2017165287A1 (en) 2016-03-22 2017-03-20 Compositions comprising choline

Publications (2)

Publication Number Publication Date
MX2018011270A MX2018011270A (es) 2019-07-08
MX392115B true MX392115B (es) 2025-03-21

Family

ID=59900796

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011270A MX392115B (es) 2016-03-22 2017-03-20 Composiciones que comprenden colina.
MX2022005380A MX2022005380A (es) 2016-03-22 2018-09-17 Composiciones que comprenden colina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005380A MX2022005380A (es) 2016-03-22 2018-09-17 Composiciones que comprenden colina.

Country Status (10)

Country Link
US (2) US11278591B2 (es)
EP (1) EP3432870A4 (es)
JP (1) JP2019510031A (es)
KR (1) KR20180121962A (es)
CN (1) CN109689035A (es)
AU (1) AU2017236879B2 (es)
BR (1) BR112018069285A2 (es)
CA (1) CA3018088A1 (es)
MX (2) MX392115B (es)
WO (1) WO2017165287A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027738A1 (en) 2015-08-11 2017-02-16 Akeso Biomedical, Inc. Antimicrobial preparation and uses thereof
US10653658B2 (en) * 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
WO2019244137A1 (en) 2018-06-22 2019-12-26 Fonterra Co-Operative Group Limited Use of polar lipids to treat or prevent gestational diabetes mellitus
CN109438268B (zh) * 2018-10-18 2021-08-03 济南蓬勃生物技术有限公司 一种酒石酸氢胆碱及其制备方法
USD886143S1 (en) 2018-12-14 2020-06-02 Nutanix, Inc. Display screen or portion thereof with a user interface for database time-machine
US10817157B2 (en) 2018-12-20 2020-10-27 Nutanix, Inc. User interface for database management services
US11816066B2 (en) 2018-12-27 2023-11-14 Nutanix, Inc. System and method for protecting databases in a hyperconverged infrastructure system
US11010336B2 (en) 2018-12-27 2021-05-18 Nutanix, Inc. System and method for provisioning databases in a hyperconverged infrastructure system
US20220257802A1 (en) * 2019-06-07 2022-08-18 Ascelia Pharma AB Compressed solid composition for mri
US11604705B2 (en) 2020-08-14 2023-03-14 Nutanix, Inc. System and method for cloning as SQL server AG databases in a hyperconverged system
US12164541B2 (en) 2020-08-28 2024-12-10 Nutanix, Inc. Multi-cluster database management system
US11907167B2 (en) 2020-08-28 2024-02-20 Nutanix, Inc. Multi-cluster database management services
US11640340B2 (en) 2020-10-20 2023-05-02 Nutanix, Inc. System and method for backing up highly available source databases in a hyperconverged system
US11604806B2 (en) 2020-12-28 2023-03-14 Nutanix, Inc. System and method for highly available database service
US11892918B2 (en) 2021-03-22 2024-02-06 Nutanix, Inc. System and method for availability group database patching
GB202112170D0 (en) * 2021-08-25 2021-10-06 Mitocholine Ltd Nutritional compositions
US11803368B2 (en) 2021-10-01 2023-10-31 Nutanix, Inc. Network learning to control delivery of updates
US12105683B2 (en) 2021-10-21 2024-10-01 Nutanix, Inc. System and method for creating template for database services
US12174856B2 (en) 2021-10-25 2024-12-24 Nutanix, Inc. Database group management
US12613857B2 (en) 2022-06-22 2026-04-28 Nutanix, Inc. Database server agent
WO2025017570A1 (en) * 2023-07-19 2025-01-23 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive composition for modulating choline dehydrogenase (chd) activity
WO2025194109A1 (en) * 2024-03-14 2025-09-18 Balchem Corporation Compositions and methods for improving brain function
CA3280511A1 (en) 2024-07-18 2026-03-01 Malian Biologicals Gmbh Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases and iron supplementation in neurodevelopmental or psychiatric disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936723B (en) * 1992-09-14 1995-08-14 Vesta Med Pty Ltd Pharmaceutical preparations for lowering homocysteine levels
WO1994009769A1 (en) 1992-11-02 1994-05-11 Buchman Alan L Use of choline in total parenteral nutrition
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US20040086564A1 (en) * 2002-10-31 2004-05-06 Richardson Paul H. Dosage forms containing stabilized choline and method for preparing same
US7429569B2 (en) 2004-01-29 2008-09-30 Fast Balance, Inc. Compositions and methods for the regulation of homocysteine levels within the body
US20090035385A1 (en) * 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
CN101522676A (zh) * 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
US8618068B2 (en) * 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
CA2905143A1 (en) * 2013-03-15 2014-09-18 Exeltis Usa, Inc. Gummy compositions for nutritional supplementation
US20150132273A1 (en) 2013-11-09 2015-05-14 Rhett Sean Daniels Nutritional Compositions and Methods for Treating Cognitive Impairment
WO2018106921A1 (en) 2016-12-09 2018-06-14 Balchem Corporation Essential nutrients and related methods

Also Published As

Publication number Publication date
US20190125828A1 (en) 2019-05-02
CN109689035A (zh) 2019-04-26
AU2017236879A1 (en) 2018-10-11
CA3018088A1 (en) 2017-09-28
JP2019510031A (ja) 2019-04-11
BR112018069285A2 (pt) 2019-01-22
MX2022005380A (es) 2022-05-19
EP3432870A1 (en) 2019-01-30
MX2018011270A (es) 2019-07-08
KR20180121962A (ko) 2018-11-09
AU2017236879B2 (en) 2022-07-21
WO2017165287A1 (en) 2017-09-28
EP3432870A4 (en) 2019-11-20
US11278591B2 (en) 2022-03-22
US20220160830A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2022005380A (es) Composiciones que comprenden colina.
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
PH12018501226A1 (en) Methods for treating huntingtons disease
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
CR20200228A (es) COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112018011216A2 (pt) métodos para inibir a conversão de colina em trimetilamina (tma)
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
BR112016006048A8 (pt) composições antimicrobianas
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
MX2018015938A (es) Metodos para inhibir la conversion de colina en trimetilamina (tma).
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
PH12017500737B1 (en) Kcnq2-5 channel activator
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
BR112015020222A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112017011256A2 (pt) métodos de preparação de concentrado em suspensão (sc) de pesticida, concentrado em suspensão (sc) de pesticida, e método de semeadura de campo